Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management

Table 4

Subset analysis of elderly population in clinical trials of immune checkpoint inhibitors for NSCLC.

Study	Age	.	HR for OS (95% CI)	HR for PFS (95% CI)
Nivolumab
CheckMate017 [38]	≥75	29	1.85 (0.76–4.51)	1.76 (0.77–4.05)
	65–74	91	0.56 (0.34–0.91)	0.51 (0.32–0.82)
	<65	152	0.52 (0.35–0.75)	0.62 (0.44–0.89)
CheckMate057 [39]	≥75	43	0.97 (0.49–1.95)	0.90 (0.43–1.87)
	65–74	200	0.94 (0.69–1.27)	0.63 (0.45–0.89)
	<65	339	0.89 (0.70–1.13)	0.81 (0.62–1.04)
Pembrolizumab
KEYNOTE024 [40]	≥65	164	NR	0.90 (0.43–1.87)
	<65	141	NR	0.45 (0.29–0.70)
KEYNOTE010 [41]	≥65	429	0.76 (0.57–1.02)	NR
	<65	604	0.63 (0.50–0.79)	NR

RR = response rate, OS = overall survival, PFS = progression free survival, and NR = not reported.